Slaap B - Search Results

1

Quality Control Process for EQ-5D-5L Valuation Studies.

Ramos-Goñi JM, Oppe M, Slaap B, Busschbach JJ, Stolk E. Ramos-Goñi JM, et al. Among authors: slaap b. Value Health. 2017 Mar;20(3):466-473. doi: 10.1016/j.jval.2016.10.012. Epub 2016 Dec 22. Value Health. 2017. PMID: 28292492 Free article.

2

Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.

Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, Busschbach J, Boye KS. Kennedy-Martin M, et al. Among authors: slaap b. Eur J Health Econ. 2020 Nov;21(8):1245-1257. doi: 10.1007/s10198-020-01195-8. Epub 2020 Jun 8. Eur J Health Econ. 2020. PMID: 32514643 Free PMC article. Review.

3

EQ-5D: a plea for accurate nomenclature.

Brooks R, Boye KS, Slaap B. Brooks R, et al. Among authors: slaap b. J Patient Rep Outcomes. 2020 Jul 3;4(1):52. doi: 10.1186/s41687-020-00222-9. J Patient Rep Outcomes. 2020. PMID: 32620995 Free PMC article.

4

Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: a preliminary study.

Slaap BR, Boshuisen ML, van Roon AM, den Boer JA. Slaap BR, et al. Int Clin Psychopharmacol. 2002 Mar;17(2):69-74. doi: 10.1097/00004850-200203000-00005. Int Clin Psychopharmacol. 2002. PMID: 11892720 Clinical Trial.

5

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.

van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es-Radhakishun F, Pande AC. van Megen HJ, et al. Among authors: slaap b. Psychopharmacology (Berl). 1997 Feb;129(3):243-8. doi: 10.1007/s002130050186. Psychopharmacology (Berl). 1997. PMID: 9084062 Clinical Trial.

6

Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.

van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A. van Megen HJ, et al. Among authors: slaap b. Psychopharmacology (Berl). 1997 Feb;129(4):357-64. doi: 10.1007/s002130050201. Psychopharmacology (Berl). 1997. PMID: 9085405 Clinical Trial.

7

Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report).

Slaap BR, van Vliet IM, Westenberg HG, den Boer JA. Slaap BR, et al. J Affect Disord. 1995 Jan 11;33(1):31-8. doi: 10.1016/0165-0327(94)00070-p. J Affect Disord. 1995. PMID: 7714306 Clinical Trial.

8

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia.

Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG, Burrows GD, Srivastava ON. Den Boer JA, et al. Among authors: slaap br. Psychopharmacology (Berl). 1995 Oct;121(3):317-22. doi: 10.1007/BF02246069. Psychopharmacology (Berl). 1995. PMID: 8584612 Clinical Trial.

9

A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.

van Vliet IM, den Boer JA, Westenberg HG, Slaap BR. van Vliet IM, et al. Among authors: slaap br. J Clin Psychopharmacol. 1996 Aug;16(4):299-306. doi: 10.1097/00004714-199608000-00005. J Clin Psychopharmacol. 1996. PMID: 8835705 Clinical Trial.

10

Pentagastrin has panic-inducing properties in obsessive compulsive disorder.

de Leeuw AS, Den Boer JA, Slaap BR, Westenberg HG. de Leeuw AS, et al. Among authors: slaap br. Psychopharmacology (Berl). 1996 Aug;126(4):339-44. doi: 10.1007/BF02247385. Psychopharmacology (Berl). 1996. PMID: 8878350 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters